Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00395512 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 655
- Enrollment target
NCT00395512 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 655 participants.
The verdict
NCT00395512, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 655 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the combination of alogliptin, once daily (QD), and pioglitazone in patients with type 2 diabetes mellitus who are inadequately controlled with diet and exercise alone.
Interventions
- DRUG Placebo
- DRUG Pioglitazone
- DRUG Alogliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 655 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00395512
The ClinicalTrials.gov registry entry for NCT00395512 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 655 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00395512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00395512 about?
NCT00395512 is a clinical study titled "Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the combination of alogliptin, once daily (QD), and pioglitazone in patients with type 2 diabetes mellitus who are inadequately controlled with diet and exercise alone.
What is the current status of trial NCT00395512?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 655 participants. The study started on 2006-11. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00395512?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), Alogliptin (DRUG).
Who is sponsoring clinical trial NCT00395512?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.